The iShares Core High Dividend ETF (NYSEARCA:HDV) leans hard on two sectors to fund its payout. Energy and pharma names account for the top four holdings, combining for 25.96% of net assets. With HDV up 19.66% year-to-date and yielding roughly 3%, I want to know whether the checks these four giants send to BlackRock are actually safe.
The Four Dividends Powering HDV
| Holding | Weight | Yield | Streak |
|---|---|---|---|
| Exxon Mobil (NYSE:XOM | XOM Price Prediction) | 8.42% | 2.65% | 43 yrs |
| Chevron (NYSE:CVX) | 6.42% | 3.67% | 38+ yrs |
| Johnson & Johnson (NYSE:JNJ) | 5.68% | 2.06% | 64 yrs (King) |
| AbbVie (NYSE:ABBV) | 5.44% | 2.80% | 13 yrs standalone |
Exxon: The Cleanest Balance Sheet in the Group
At $4.08 per share against $5.85 in trailing 12-month EPS, Exxon runs a 69.74% earnings payout ratio. Fiscal year 2025 free cash flow of $26.13 billion easily covered the dividend, and interest coverage of 56.28x is extraordinary by any measure. CEO Darren Woods highlighted “an industry-leading balance sheet that gives us unmatched flexibility.” Rating: Very Safe.
Chevron: Hess Cash Flow Reset the Math
After the Hess close, Chevron delivered $18.10 billion in free cash flow during the second quarter of 2026, representing a 272% increase, and the company reduced debt by $8.41 billion in the same quarter. Net Debt to EBITDA sits at 1.08x, with interest coverage of 13.70x. CEO Mike Wirth flagged that the “$3 billion in annual run-rate savings” target was hit six months ahead of schedule. The payout ratio is elevated at $6.98 on $10.18 in earnings, though cash flows comfortably cover it. Rating: Safe.
Johnson & Johnson: The Dividend King Earns Its Crown
With an earnings payout ratio of 60.16% on $8.71 EPS, JNJ leaves itself a real cushion. Fiscal year 2025 free cash flow of $19.70 billion and raised 2026 guidance of $11.45 to $11.65 adjusted EPS underwrite the payout, even with first-quarter litigation charges in the mix. CEO Joaquin Duato called 2026 “a year of accelerated growth and impact.” An AAA credit rating and 64 consecutive dividend raises seal the case. Rating: Very Safe.
AbbVie: Growing but Leveraged
At $6.83 annually, ABBV yields 2.80%. The trailing P/E of 69 overstates the strain, since the forward P/E is 18, though Net Debt to EBITDA of 2.26x and negative book equity from the Allergan deal keep me cautious. Skyrizi and Rinvoq brought in a combined $8.04 billion in the second quarter of 2026, and they are replacing Humira faster than expected. Rating: Safe with a watchlist tag.
The Verdict on HDV’s Income Engine
Three of the four checks that fund HDV are rock solid. The income profile looks durable as long as crude stays above the EIA’s $79/b 2027 forecast and AbbVie’s immunology handoff holds together. The setup starts to weaken if oil retraces sharply and ABBV’s leverage bites at the same time.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks